AU2016261599B2 - Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device - Google Patents

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device Download PDF

Info

Publication number
AU2016261599B2
AU2016261599B2 AU2016261599A AU2016261599A AU2016261599B2 AU 2016261599 B2 AU2016261599 B2 AU 2016261599B2 AU 2016261599 A AU2016261599 A AU 2016261599A AU 2016261599 A AU2016261599 A AU 2016261599A AU 2016261599 B2 AU2016261599 B2 AU 2016261599B2
Authority
AU
Australia
Prior art keywords
antibody
capsule
preparation
tissue penetrating
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016261599A
Other languages
English (en)
Other versions
AU2016261599A1 (en
Inventor
Mir Hashim
Mir Imran
Radhika KORUPOLU
Elaine TO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rani Therapeutics LLC
Original Assignee
Rani Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rani Therapeutics LLC filed Critical Rani Therapeutics LLC
Publication of AU2016261599A1 publication Critical patent/AU2016261599A1/en
Assigned to RANI THERAPEUTICS, LLC reassignment RANI THERAPEUTICS, LLC Request for Assignment Assignors: INCUBE LABS, LLC
Application granted granted Critical
Publication of AU2016261599B2 publication Critical patent/AU2016261599B2/en
Priority to AU2021269453A priority Critical patent/AU2021269453B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016261599A 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device Active AU2016261599B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021269453A AU2021269453B2 (en) 2015-05-08 2021-11-22 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
US62/159,134 2015-05-08
PCT/US2016/031548 WO2016183040A1 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021269453A Division AU2021269453B2 (en) 2015-05-08 2021-11-22 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Publications (2)

Publication Number Publication Date
AU2016261599A1 AU2016261599A1 (en) 2017-11-23
AU2016261599B2 true AU2016261599B2 (en) 2021-08-26

Family

ID=57248408

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016261599A Active AU2016261599B2 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2021269453A Expired - Fee Related AU2021269453B2 (en) 2015-05-08 2021-11-22 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021269453A Expired - Fee Related AU2021269453B2 (en) 2015-05-08 2021-11-22 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Country Status (6)

Country Link
EP (1) EP3294273A4 (enExample)
JP (2) JP7185401B2 (enExample)
CN (1) CN107835682A (enExample)
AU (2) AU2016261599B2 (enExample)
CA (1) CA2984422C (enExample)
WO (1) WO2016183040A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
CN108401419A (zh) * 2015-09-08 2018-08-14 因库博实验室有限责任公司 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂
WO2018112256A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
BR112021012959A2 (pt) * 2018-12-31 2021-09-08 Rani Therapeutics, Llc Preparações de agente terapêutico para a liberação em um lúmen do trato intestinal pela utilização de um dispositivo de liberação de fármaco engolível
EP4188508A2 (en) * 2020-07-30 2023-06-07 Verily Life Sciences LLC Pill with needle delivery system having outwardly expanding mechanical actuation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130165859A1 (en) * 2010-12-23 2013-06-27 Incube Labs, Llc Device, system and methods for the oral delivery of therapeutic compounds
US20140221912A1 (en) * 2009-12-24 2014-08-07 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
JP2010502759A (ja) * 2006-09-12 2010-01-28 コスモ・テクノロジーズ・リミテツド タンパク質物質の経口または直腸投与のための医薬組成物
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
CN105999526B (zh) 2009-12-24 2019-07-05 拉尼医疗有限公司 可吞咽式药剂递送装置和药剂递送方法
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
EP3653224A1 (en) 2011-06-29 2020-05-20 Rani Therapeutics, LLC Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2840487C (en) 2011-06-29 2022-09-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
AU2013334740A1 (en) * 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
CN107072955B (zh) * 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
CN113546036A (zh) * 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221912A1 (en) * 2009-12-24 2014-08-07 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US20130165859A1 (en) * 2010-12-23 2013-06-27 Incube Labs, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LONNBERG, LONE SKOV, CLAUS ZACHARIAE: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, pages 251, XP055328086, DOI: 10.2147/CCID.S67534 *
MCLEAN, LP ET AL.: "Combined Blockade of IL -17A and IL -17F May Prevent the Development of Experimental Colitis.", IMMUNOTHERAPY, FUTURE MEDICINE LTD., GB, vol. 5, no. 9, 1 January 2013 (2013-01-01), GB, pages 1 - 6, XP009507133, ISSN: 1750-743X *

Also Published As

Publication number Publication date
EP3294273A4 (en) 2018-12-05
CA2984422A1 (en) 2016-11-17
AU2016261599A1 (en) 2017-11-23
JP7185401B2 (ja) 2022-12-07
JP2021042239A (ja) 2021-03-18
CA2984422C (en) 2023-10-17
AU2021269453A1 (en) 2021-12-16
EP3294273A1 (en) 2018-03-21
WO2016183040A1 (en) 2016-11-17
CN107835682A (zh) 2018-03-23
JP2018520995A (ja) 2018-08-02
JP7232805B2 (ja) 2023-03-03
AU2021269453B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
US20230174639A1 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2021269453B2 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20240109959A1 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20220339095A1 (en) Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10300010B2 (en) Methods for delivering entanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10307579B2 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10487145B2 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2012275112B2 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2016320867B2 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RANI THERAPEUTICS, LLC

Free format text: FORMER APPLICANT(S): INCUBE LABS, LLC

FGA Letters patent sealed or granted (standard patent)